Ivrenas 200 mg (Tablet)

Indications

• Treatment of novel or re-emerging pandemic influenza virus infections

Description

• Approved for manufacture and sale in Japan as an influenza antiviral
• Selectively inhibits the RNA polymerase of the influenza virus

Pharmacology

• Metabolized into favipiravir ribosyl triphosphate (favipiravir RTP) by an intracellular enzyme
• Effective against all types and sub-types of human influenza A, B, and C viruses in vitro

Dosage & Administration

• Usual adult dosage is 1600 mg of Favipiravir administered orally twice daily on Day 1
• Total treatment duration should be 5 days

Interaction

• In animal studies, decreased RBC production
• Increased liver function parameters such as AST, ALP, ALT, and total bilirubin

Contraindications

• Contraindicated for pregnant women and women who may possibly be pregnant

Side Effects

• Most common side effects are Diarrhea and increase of blood uric acid levels

Pregnancy & Lactation

• May cause delayed development or death of embryos during the early stage of pregnancy
• Should not be given during pregnancy

Precautions & Warnings

• Should not be given in pregnant women
• Requirement of the confirmation of non-pregnancy in women of childbearing potential
• Thorough contraception measures from the start of the treatment to 7 days after the end of the treatment

Use in Special Populations

• Only approved as an experimental drug
• Further studies needed about its efficacy and toxic reactions in children

Overdose Effects

• In animal studies, decreased RBC production
• Increased liver function parameters such as AST, ALP, ALT, and total bilirubin

Therapeutic Class

• Anti-viral drugs

Storage Conditions

• Keep below 30°C temperature
• Protected from light & moisture
• Keep out of the reach of children

Related Brands

• Favirest 200 mg (Tablet) - everest-pharmaceuticals-ltd